Casebia Therapeutics appoints James W. Burns as CEO
Dr. Burns brings to Casebia Therapeutics nearly 30 years of R&D experience in the biopharmaceutical industry and a proven track record of leading R&D organizations that have successfully delivered therapeutics to patients.
Prior to joining Casebia, Dr. Burns spent the bulk of his career at Sanofi-Genzyme. First joining Genzyme in 1986, he had several leadership roles with increasing responsibility.
Most recently as the Head of Sanofi’s North American R&D Hub, he was responsible for coordinating R&D operations across key therapeutic areas.
Dr. Burns is a former board member of MassBio, a member of the U.S. National Academy of Engineering and is Chair of the External Advisory Committee for the Biomedical Engineering Department at Boston University.
He served from 1996-1999 as the Industry Representative for the Food and Drug Administration General and Plastic Surgery Panel.
Dr. Burns earned a Bachelor of Science degree in Biology from Purdue University, and Master of Science and Doctorate degrees in Bioengineering from the University of Illinois-Chicago, where his thesis work focused on drug delivery.
Following his graduate studies, Dr. Burns was a post-doctoral researcher at the University of Florida. ■
LATEST MOVES FROM Massachusetts
- bluebird bio appoints Mary Lynne Hedley to board
- Welch's names Lesya Lysyj president, US
- Liberty Mutual appoints Gregg Cunningham as vice president
- Voyager Therapeutics appoints Matthew P. Ottmer as COO
- Ocular Therapeutix appoints Michael Goldstein as CMO
More inside POST
$4 million for energy-strapped Gaza Politics